Mohammed Nader Shalaby

Prof. Dr. Mohammed Nader Shalaby

Biological Science And Sports Health, Suez Canal University, Ismailia, Al Ismā‘īlīyah, Egypt
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2022 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
ANAdel Naimi
Adel Naimi
RMRebar N. Mohammed
Rebar N. Mohammed
ARAhmed Raji
Ahmed Raji
Supat ChupraditSupat Chupradit
Supat Chupradit
AYAlexei Valerievich Yumashev
Alexei Valerievich Yumashev
EREhsan Razeghian
Ehsan Razeghian
The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint (IC) proteins, which act as a potent suppressor of the immune system by a myriad of mechanisms. After that, scientists focused on the immune checkpoint molecules mainly. Thereby, much effort was spent to progress novel strategies for suppressing these inhibitory axes, resulting in the evolution of immune checkpoint inhibitors (ICIs). Then, ICIs have become a promising approach and shaped a paradigm shift in tumor immunotherapies. CTLA-4 plays an influential role in attenuation of the induction of naïve and memory T cells by engagement with its responding ligands like B7-1 (CD80) and B7-2 (CD86). Besides, PD-1 is predominantly implicated in adjusting T cell function in peripheral tissues through its interaction with programmed death-ligand 1 (PD-L1) and PD-L2. Given their suppressive effects on anti-tumor immunity, it has firmly been documented that ICIs based therapies can be practical and rational therapeutic approaches to treat cancer patients. Nonetheless, tumor inherent or acquired resistance to ICI and some treatment-related toxicities restrict their application in the clinic. The current review will deliver a comprehensive overview of the ICI application to treat human tumors alone or in combination with other modalities to support more desired outcomes and lower toxicities in cancer patients.

7 April 2022 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
Mohammad Javed AnsariMohammad Javed Ansari
Mohammad Javed Ansari
Dmitry BokovDmitry Bokov
Dmitry Bokov
AMAlexander A. Markov
Alexander A. Markov
Abduladheem Turki JalilAbduladheem Turki Jalil
Abduladheem Turki Jalil
Mohammed Nader ShalabyMohammed Nader Shalaby
Mohammed Nader Shalaby
MDMehdi Dadashpour
Mehdi Dadashpour
Abnormal vasculature is one of the most conspicuous traits of tumor tissue, largely contributing to tumor immune evasion. The deregulation mainly arises from the potentiated pro-angiogenic factors secretion and can also target immune cells' biological events, such as migration and activation. Owing to this fact, angiogenesis blockade therapy was established to fight cancer by eliminating the nutrient and oxygen supply to the malignant cells by impairing the vascular network. Given the dominant role of vascular-endothelium growth factor (VEGF) in the angiogenesis process, the well-known anti-angiogenic agents mainly depend on the targeting of its actions. However, cancer cells mainly show resistance to anti-angiogenic agents by several mechanisms, and also potentiated local invasiveness and also distant metastasis have been observed following their administration. Herein, we will focus on clinical developments of angiogenesis blockade therapy, more particular, in combination with other conventional treatments, such as immunotherapy, chemoradiotherapy, targeted therapy, and also cancer vaccines.

21 June 2022 in International Immunopharmacology
Verified
Journal Article
Closed access
SJSaade Abdalkareem Jasim
Saade Abdalkareem Jasim
MCMaria Catalan Catalan
Maria Catalan Catalan
ARAndrés Alexis Ramírez-Coronel
Andrés Alexis Ramírez-Coronel
Walid KamalWalid Kamal
Walid Kamal
MAMurtadha Hasan Abed
Murtadha Hasan Abed
RMRasoul Mirzaei
Rasoul Mirzaei

19 February 2022 in International Immunopharmacology
Verified
Journal Article
Closed access
HHHuldani Huldani
Huldani Huldani
SJSaade Abdalkareem Jasim
Saade Abdalkareem Jasim
DBDmitry Olegovich Bokov
Dmitry Olegovich Bokov
Walid KamalWalid Kamal
Walid Kamal
Mohammed Nader ShalabyMohammed Nader Shalaby
Mohammed Nader Shalaby
MQMaytham T. Qasim
Maytham T. Qasim

18 May 2022 in Phytotherapy Research
Verified
Journal Article
Closed access
ENElyas Nattagh
Elyas Nattagh
AGAlireza Gheflati
Alireza Gheflati
HBHanieh Barghchi
Hanieh Barghchi
PRPegah Rahbarinejad
Pegah Rahbarinejad
KHKadda Hachem
Kadda Hachem
NPNaseh Pahlavani
Naseh Pahlavani

17 May 2022 in Analytical Biochemistry
Verified
Journal Article
Closed access
SCSupat Chupradit
Supat Chupradit
Mahyuddin K. M. NasutionMahyuddin K. M. Nasution
Mahyuddin K. M. Nasution
HRHeshu Sulaiman Rahman
Heshu Sulaiman Rahman
Wanich SuksatanWanich Suksatan
Wanich Suksatan
Abduladheem Turki JalilAbduladheem Turki Jalil
Abduladheem Turki Jalil
RBRamtin Bidares
Ramtin Bidares